Modulation of adrenergic receptors during regression of cardiac hypertrophy

J Hypertens. 1994 Dec;12(12):1353-7.

Abstract

Objective: To determine whether alpha 1- or beta-adrenergic receptors are altered during regression of cardiac hypertrophy produced by antihypertensive agents.

Design and methods: Cardiac hypertrophy was induced in rats by aortic banding. After 6 weeks banding the rats were treated with an angiotensin converting enzyme (ACE) inhibitor (enalapril), an alpha 1-adrenergic antagonist (bunazosin) or a beta-adrenergic antagonist (propranolol) for 6 weeks to induce regression. The numbers of alpha 1- and beta-adrenergic receptors, haemodynamics, tissue noradrenaline content and tissue ACE activity were measured.

Results: Regression of cardiac hypertrophy occurred after treatment of aortic banded rats with a high dose of enalapril, bunazosin or propranolol, and was accompanied by a reduction in systolic blood pressure. The number of alpha 1- or beta-adrenergic receptors was unchanged by propranolol treatment, but the number of alpha 1-adrenergic receptors was increased in the hearts of rats treated with bunazosin. A low dose of enalapril (3 mg/kg body weight) caused regression of hypertrophy without a concomitant reduction in blood pressure, and decreased the number of alpha 1-adrenergic receptors. The dissociation constants for alpha 1- and beta-adrenergic receptors were not different among the experimental groups, and the positive derivatives of left ventricular pressure was unaltered in rats treated with a low dose of enalapril but was reduced by the other drugs.

Conclusion: Of the three drugs tested, only the low dose of enalapril affected adrenergic receptors during regression of cardiac hypertrophy, causing a decrease in alpha 1-adrenergic receptor number without a reduction in blood pressure. This effect may be explained by non-haemodynamic actions of the ACE inhibitor enalapril, probably by modulation of peripheral sympathetic activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Cardiomegaly / drug therapy
  • Cardiomegaly / metabolism*
  • Iodocyanopindolol
  • Male
  • Norepinephrine / analysis
  • Pindolol / analogs & derivatives
  • Pindolol / metabolism
  • Prazosin / metabolism
  • Rats
  • Rats, Wistar
  • Receptors, Adrenergic, alpha-1 / analysis*
  • Receptors, Adrenergic, alpha-1 / drug effects
  • Receptors, Adrenergic, beta / analysis*
  • Receptors, Adrenergic, beta / drug effects

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Receptors, Adrenergic, alpha-1
  • Receptors, Adrenergic, beta
  • Iodocyanopindolol
  • Pindolol
  • Norepinephrine
  • Prazosin